Cargando…
STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes
BACKGROUND: Mutations in STAG2 cause complete loss of STAG2 protein in approximately one-third of non–muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest that loss of STAG2 expression is a good prognostic i...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051973/ https://www.ncbi.nlm.nih.gov/pubmed/35495284 http://dx.doi.org/10.1016/j.euros.2022.02.004 |
_version_ | 1784696683732402176 |
---|---|
author | Gordon, Naheema S. Humayun-Zakaria, Nada Goel, Anshita Abbotts, Ben Zeegers, Maurice P. Cheng, K.K. James, Nicholas D. Arnold, Roland Bryan, Richard T. Ward, Douglas G. |
author_facet | Gordon, Naheema S. Humayun-Zakaria, Nada Goel, Anshita Abbotts, Ben Zeegers, Maurice P. Cheng, K.K. James, Nicholas D. Arnold, Roland Bryan, Richard T. Ward, Douglas G. |
author_sort | Gordon, Naheema S. |
collection | PubMed |
description | BACKGROUND: Mutations in STAG2 cause complete loss of STAG2 protein in approximately one-third of non–muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest that loss of STAG2 expression is a good prognostic indicator in NMIBC. OBJECTIVE: To confirm the relationship between STAG2 protein expression and clinical outcomes and tumour characteristics in NMIBC. DESIGN, SETTING, AND PARTICIPANTS: IHC was used to determine STAG2 expression in 748 incident urothelial bladder cancers (UBCs) and recurrence-free, progression-free, and disease-specific survival were compared for patients with and without STAG2 loss. Exome and RNA sequencing were used to explore links between STAG2 loss and tumour molecular characteristics. RESULTS AND LIMITATIONS: STAG2 loss was observed in 19% of UBC patients and was 1.6-fold more common among female patients. Loss was frequent among grade 1 pTa tumours (40%), decreasing with stage and grade to only 5% among grade 3 pT2+ tumours. Loss was associated with fewer copy-number changes and less aggressive expression subtypes. In UBC, STAG2 loss was a highly significant prognostic indicator of better disease-free survival but was not independent of stage and grade. STAG2 loss was not a statistically significant predictor of NMIBC recurrence. STAG2 loss was significantly associated with better progression-free survival in NMIBC and appeared to be more prognostic for males than for females. CONCLUSIONS: A simple IHC-based STAG2 test shows promise for identifying NMIBC patients at lower risk of progression to MIBC for whom more conservative treatments may be suitable. PATIENT SUMMARY: A protein called STAG2 is frequently lost in early bladder cancers, most often in less aggressive tumours. STAG2 loss is easily measured and could be used as a biomarker to help guide treatment decisions. |
format | Online Article Text |
id | pubmed-9051973 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-90519732022-04-30 STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes Gordon, Naheema S. Humayun-Zakaria, Nada Goel, Anshita Abbotts, Ben Zeegers, Maurice P. Cheng, K.K. James, Nicholas D. Arnold, Roland Bryan, Richard T. Ward, Douglas G. Eur Urol Open Sci Urothelial Cancer BACKGROUND: Mutations in STAG2 cause complete loss of STAG2 protein in approximately one-third of non–muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest that loss of STAG2 expression is a good prognostic indicator in NMIBC. OBJECTIVE: To confirm the relationship between STAG2 protein expression and clinical outcomes and tumour characteristics in NMIBC. DESIGN, SETTING, AND PARTICIPANTS: IHC was used to determine STAG2 expression in 748 incident urothelial bladder cancers (UBCs) and recurrence-free, progression-free, and disease-specific survival were compared for patients with and without STAG2 loss. Exome and RNA sequencing were used to explore links between STAG2 loss and tumour molecular characteristics. RESULTS AND LIMITATIONS: STAG2 loss was observed in 19% of UBC patients and was 1.6-fold more common among female patients. Loss was frequent among grade 1 pTa tumours (40%), decreasing with stage and grade to only 5% among grade 3 pT2+ tumours. Loss was associated with fewer copy-number changes and less aggressive expression subtypes. In UBC, STAG2 loss was a highly significant prognostic indicator of better disease-free survival but was not independent of stage and grade. STAG2 loss was not a statistically significant predictor of NMIBC recurrence. STAG2 loss was significantly associated with better progression-free survival in NMIBC and appeared to be more prognostic for males than for females. CONCLUSIONS: A simple IHC-based STAG2 test shows promise for identifying NMIBC patients at lower risk of progression to MIBC for whom more conservative treatments may be suitable. PATIENT SUMMARY: A protein called STAG2 is frequently lost in early bladder cancers, most often in less aggressive tumours. STAG2 loss is easily measured and could be used as a biomarker to help guide treatment decisions. Elsevier 2022-03-04 /pmc/articles/PMC9051973/ /pubmed/35495284 http://dx.doi.org/10.1016/j.euros.2022.02.004 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Urothelial Cancer Gordon, Naheema S. Humayun-Zakaria, Nada Goel, Anshita Abbotts, Ben Zeegers, Maurice P. Cheng, K.K. James, Nicholas D. Arnold, Roland Bryan, Richard T. Ward, Douglas G. STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes |
title | STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes |
title_full | STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes |
title_fullStr | STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes |
title_full_unstemmed | STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes |
title_short | STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes |
title_sort | stag2 protein expression in non–muscle-invasive bladder cancer: associations with sex, genomic and transcriptomic changes, and clinical outcomes |
topic | Urothelial Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051973/ https://www.ncbi.nlm.nih.gov/pubmed/35495284 http://dx.doi.org/10.1016/j.euros.2022.02.004 |
work_keys_str_mv | AT gordonnaheemas stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes AT humayunzakarianada stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes AT goelanshita stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes AT abbottsben stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes AT zeegersmauricep stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes AT chengkk stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes AT jamesnicholasd stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes AT arnoldroland stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes AT bryanrichardt stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes AT warddouglasg stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes |